Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl
Isabelle Mohr(Heidelberg University), Karl Heinz Weiss(Heidelberg University), Mickaël Alexandre Obadia(Fondation Ophtalmologique Adolphe de Rothschild), Erwan Morvan(Fondation de Rothschild), Gerald Denk(Ludwig-Maximilians-Universität München), Hélène Bourhis(Ludwig-Maximilians-Universität München), Uta Merle(Heidelberg University), France Woimant(Fondation de Rothschild), Müzeyyen Morgil(Krankenhaus Salem), Aurélia Poujois(Fondation Ophtalmologique Adolphe de Rothschild)
Cited by 10
Related Papers
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Cerebral venous thrombosis associated with COVID-19 infection: Causality or coincidence?
|Journal of Neuroradiology|2020|95
Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease
|Gastroenterology|2021|82
Anterior cerebral artery embolism during thrombectomy increases disability and mortality
|Journal of NeuroInterventional Surgery|2018|56